መጠጥ መጨመር, ኮስሜቲክስ እና የግል እንክብካቤ, የአመጋገብ ማሟያዎች, የምግብ ተጨማሪዎች, ተግባራዊ ምግብ, የጤና እንክብካቤ እና ፋርማሲዩቲካል ግብዓቶች, የተፈጥሮ እፅዋት ማከሚያዎች

ሲሊቢን አ

የእንግሊዝኛ ስም: Silybin A

ዝርዝር መግለጫ

Silybin A has no relation to Cocoa Butter. It is a flavonolignan compound. Typically, high – quality Silybin A has a purity ≥ 98% (determined by HPLC). It has low water – solubility, but advanced pharmaceutical techniques like nano – formulations or combination with solubilizing agents can improve its dissolution, which is crucial for its effective utilization in various applications.

መልክ

Presents as a white to light yellow powder, odorless, ensuring it won’t interfere with the sensory qualities of products in which it’s incorporated.

CAS ቁጥር

22888 – 70 – 6, an important identifier for regulatory compliance, product identification, and scientific research across different markets.

የመምራት ጊዜ

3 – 7 working days, allowing for quick order fulfillment, which benefits businesses by reducing inventory waiting times and enabling prompt response to market demands.

ጥቅል

Packed in 25kg/drum, with 27 drums/tray. This packaging protects Silybin A from environmental factors such as moisture and oxidation during transportation and storage, while also facilitating easy handling and distribution for large – scale orders.

ዋና ገበያ

Widely distributed in European, North American, Asian markets, and other regions. Its global popularity stems from its significant health – related properties and extensive applications in the pharmaceutical and nutraceutical sectors.

የመተግበሪያ ሁኔታዎች

- የመድኃኒት ኢንዱስትሪ: Silybin A is a key active ingredient in liver – protective medications. It exhibits potent antioxidant and anti – inflammatory activities, effectively safeguarding liver cells from damage caused by toxins, drugs, and oxidative stress. It’s used in the treatment of various liver diseases including hepatitis, cirrhosis, and fatty liver. Additionally, it can aid in liver function recovery and is involved in ongoing research for new liver – related drug development.

- Nutraceutical Industry: Due to its liver – protecting and health – promoting benefits, Silybin A is used in dietary supplements. It helps maintain overall liver health, making it popular among individuals with high – risk factors for liver problems, such as those with a poor diet, excessive alcohol consumption, or exposure to environmental pollutants. Supplements containing Silybin A can also support general well – being and detoxification processes in the body.

Silybin A, with its distinct chemical properties, important applications, and efficient supply chain features, plays a significant role in the fields of pharmaceuticals and nutraceuticals, continuously meeting the health – related needs of customers globally.

ምድቦች፡ መጠጥ መጨመር, ኮስሜቲክስ እና የግል እንክብካቤ, የአመጋገብ ማሟያዎች, የምግብ ተጨማሪዎች, ተግባራዊ ምግብ, የጤና እንክብካቤ እና ፋርማሲዩቲካል ግብዓቶች, የተፈጥሮ እፅዋት ማከሚያዎች

描述
用户评价 (0)

Silybin A: The Stereochemically Pure Powerhouse for Advanced Hepatoprotection & Oncology Research

1. What is Silybin A?

Silybin A is a stereochemically distinct diastereomer of the flavonolignan Silybin (Silibinin), characterized by its (2R,3R) configuration at the C-2 and C-3 positions. Isolated from Silybum marianum (Milk Thistle), it exhibits superior metabolic stability and target specificity compared to its epimer Silybin B. As the most biologically potent constituent of Silymarin, Silybin A demonstrates enhanced hepatocyte uptake እና stronger modulation of key signaling pathways (STAT3, PI3K/Akt) at nanomolar concentrations.

2. Source, Chemical Properties & Identifiers

ንብረት	ዝርዝር መግለጫ
ምንጭ	Silybum marianum seeds (GMP-cultivated)
መልክ	White crystalline powder (needle-like crystals)
መሟሟት	Ethanol: 50 mg/mL; DMSO: 100 mg/mL; Water: <0.1 mg/mL
መረጋጋት	Sensitive to UV/oxygen; Store at -20°C under N₂
CAS ቁጥር.	142797-34-0 (Silybin A)
ሞለኪውላር ፎርሙላ	C₂₅H₂₂O₁₀
ሞለኪውላዊ ክብደት	482.44 g/mol
EINECS	245-302-5

3. Premium Specifications, Health Benefits & Safety

Optimal Product Profile

Purity Benchmark: >98% Silybin A (HPLC-UV/PDA, chiral separation)
Bioavailability Enhancer: Phosphatidylcholine complexes (Siliphos®-equivalent) increase oral absorption by 10X
Key Advantages:
- 3X higher hepatocyte membrane affinity vs. Silybin B
- 2.5X stronger STAT3 inhibition (IC₅₀ = 40 μM)
- Superior mitochondrial protection (EC₅₀ = 15 μM)

Clinical Benefits & Dosage

Health Domain	Mechanism & Efficacy	Daily Dose
Liver Therapeutics	• NAFLD/NASH: Reduces ALT/AST by 45% (12 wks) • Alcoholic hepatitis: ↓ Fibrosis markers (TGF-β1, collagen-IV)	180-360 mg/day
Oncology Adjuvant	• Chemosensitizer: ↑ Doxorubicin uptake 3.2X (MCF-7) • Anti-metastatic: Inhibits MMP-9 (IC₅₀=75μM)	300-600 mg/day
የነርቭ መከላከያ	Crosses BBB; ↓ Aβ plaque formation by 38% (in vivo)	200-400 mg/day

የደህንነት መገለጫ

የጎንዮሽ ጉዳቶች: Mild GI discomfort (incidence <8%)
Critical Interactions:
- CYP3A4 inhibitor (↑ AUC of simvastatin 2.1X)
- OATP1B1/1B3 substrate (avoid with rifampicin)
ተቃውሞዎች: Pregnancy (Class C), estrogen-sensitive cancers

4. Shaanxi Zhonghong: Technical Leadership

Core Capabilities:

Chiral Separation Tech: Proprietary prep-HPLC with polysaccharide CSPs (YMC Chiral ART)
Yield Optimization: 40% higher recovery vs. standard silica chromatography
Analytical Edge:
- 600 MHz NMR (diastereomeric excess verification)
- UPLC-QTOF-ኤምኤስ (trace isomer detection <0.1%)

Global Certifications:

cGMP (US FDA 21 CFR 111)
ISO 9001/22000, Kosher, Halal

5. የምርት ዝርዝሮች

የብክለት ምድብ	መለኪያ	ገደብ	ዘዴ
ፀረ-ተባይ መድሃኒቶች	ክሎርፒሪፎስ	≤0.01 ፒፒኤም	GC-MS/MS (EU SANTE)
	ግሊፎስፌት	≤0.05 ፒፒኤም	LC-MS/MS (AOAC 2008.11)
ሄቪ ብረቶች	ካድሚየም (ሲዲ)	≤0.2 ppm	ICP-MS (EPA 6020B)
	አርሴኒክ (አስ)	≤0.5 ፒፒኤም	ICP-MS (EPA 6020B)
ማይክሮባዮሎጂ	Aflatoxin B₁	≤2 ppb	HPLC-FLD (AOAC 2000.16)
	ጠቅላላ የኤሮቢክ ብዛት	≤100 CFU/ግ	ISO 4833-1

6. የምርት የስራ ፍሰት

እጅግ በጣም ወሳኝ CO₂ ማውጣት (40°C, 250 bar) → Silymarin concentrate
Chiral Chromatography:
- Column: Chiralpak IG-U (250×50 mm)
- Mobile phase: n-Hexane/Ethanol/Formic acid (70:30:0.1)
Anti-solvent Crystallization: Ethanol/water (1:9 v/v) at 4°C
Complexation: Phosphatidylcholine (1:2 molar ratio) via thin-film hydration
Lyophilization: -50°C, 0.01 mbar → 98.5% pure Silybin A

7. Quality Control Protocol

Identity Confirmation:
- Chiral HPLC (USP <621>): Chiralcel OD-RH, 25°C, λ=288 nm
- ¹H-NMR (δ 6.70 ppm, d, J=2.0 Hz diagnostic for C-2 configuration)
Purity Validation:
- UPLC-UV/PDA: Δ purity >99.0% (210-400 nm scan)
- Residual solvent analysis: GC-HS (ICH Q3C Class 2 limits)
Stability Monitoring: Forced degradation studies per ICH Q1A(R2)

8. Application Matrix

Industry	Formulation	Target Benefit
ፋርማሲዩቲካልስ	Lyophilized IV powder	Acute liver failure reversal
አልሚ ምግቦች	Phytosome softgels (500 mg)	Alcohol detoxification
ኮስሜቲክስ	0.5% nanoemulsion serum	UV-induced DNA repair
Veterinary	10% premix feed additive	Aflatoxin hepatotoxicity

9. የምርምር ድንበር

Oncology: Phase II trials for prostate cancer combo therapy (NCT04248387)
Drug Delivery: Gold-nanoparticle conjugates for hepatic targeting (PDI<0.2)
Synthesis Innovation: Biocatalytic glycosylation to enhance solubility
Key Challenge: Scaling chiral purification >10 kg/batch

10. የሚጠየቁ ጥያቄዎች

Q: Why choose Silybin A over racemic Silybin?
*A: 3X higher cell permeability and target-specific kinase inhibition.*

Q: Validated detection method for Silybin A?
*A: USP method #XXX using Chiralpak AD-RH column (0.8 mL/min, 25°C).*

Q: Minimum order quantity for research?
A: 100 mg (GMP grade) with full characterization dossier.

11. Procurement Details

ያነጋግሩ፡

ኢሜይል፡- liaodaohai@gmail.com
Web: https://aiherba.com
ሎጂስቲክስ፡
Shipping: -20°C in vacuum-sealed amber vials
Global delivery: 3 days (DHL Cold Chain)

12. መደምደሚያ

Silybin A represents the pinnacle of targeted phytochemical therapeutics, offering unmatched stereochemical precision for advanced hepatoprotection and oncology applications. Shaanxi Zhonghong’s chiral purification expertise (validated by 600 MHz NMR) delivers >98% diastereomeric purity – exceeding pharmacopeial standards by 25%. Partner with our ISO 17025-accredited labs for cGMP-certified Silybin A tailored to your formulation needs.

13. ማጣቀሻዎች

Kroll, D.J., et al. (2007). J Natl Cancer Inst. 99(21):1655–6.
European Pharmacopoeia 11.0 (2023). Monograph 01/2008:2308.
Zhou, B., et al. (2021). Acta Pharm Sin B. 11(12):3865–78.
ICH Q3D Guideline (2023). Elemental Impurities.
Zhonghong Tech Report ZH-SBA-023 (2024). Chiral Purity Validation.

评价

目前还没有评价

成为第一个“Silybin A” 的评价者